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Introduction
Pain is a complex response by the organism to maintain body integrity. Chronic pain conditions such as neuropathic pain arise as a consequence of a lesion or disease of the somatosensory system, leading to the perpetuation of pain symptoms [1] [2] [3] . Spontaneous behavior in response to normally innocuous tactile stimuli (allodynia) and exaggerated pain in response to noxious stimuli (hyperalgesia) characterize neuropathic pain [2, 4, 5] . The pathogenesis of neuropathic pain is characterized by reorganization of the spinal cord due to changes in synaptic transmission and activation of neurons and glial cells such as astrocytes and microglia [6] [7] [8] . Once activated, these cells release several pro-inflammatory/nociceptive cytokines [9] that activate and/or sensitize nociceptive neurons in the spinal cord, further contributing to pathological pain [4] .
Furthermore, cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-33 (IL-33) induce the sensitization and hyperexcitability of nociceptive neurons [10] [11] [12] [13] [14] . Notably, chronic pain represents a therapeutic challenge for clinicians due to severity, frequency, limited effective treatment and several side effects [1, 2, 15, 16] .
Nitroxyl or nitrosyl hydride (HNO) is one-electron more reduced than nitric oxide (NO).
Importantly, nitroxyl exhibits different chemical and pharmacological properties compared to NO [17] [18] [19] and reactive oxygen and other nitrogen species [20] . Although nitroxyl and NO are different chemical entities, they nonetheless, can activate similar signaling pathways. For instance, nitroxyl can activate soluble guanylate cyclase (sGC), a primary NO target [21] [22] [23] [24] . As such, the nitroxyl donor, Angeli`s salt (Na 2 N 2 O 3 ; AS), reduces inflammatory hyperalgesia and spontaneous overt pain-like behavior by activating the cGMP/PKG/ATP-sensitive potassium channels [25, 26] . The analgesic effect of AS depends on nitroxyl since it was inhibited by Lcysteine (a nitroxyl scavenger) [25, 26] .
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AS significantly reduces the acute inflammatory hyperalgesia induced by carrageenan, lipopolysaccharide (LPS), TNF-α, IL-1β, and prostaglandin E 2 as well as diminishes the overt pain-like behavior induced by acetic acid, phenyl-p-benzoquinone and formalin [25, 26] . However, it is not known whether AS exerts analgesic activity capable of controlling neuropathic pain. Thus, the acute and chronic analgesic effects of AS on chronic constriction injury of the sciatic nerve (CCI) in mice were evaluated. Furthermore, whether the analgesic effect of AS depends on activating the cGMP/PKG/ATP-sensitive potassium channel pathway and modulating spinal cord glial cell activity (astrocytes and microglia), and cytokines (TNF-α, IL-1β, and IL-33/ST2) was tested.
Material and methods
Animals
All experiments were performed with the approval of the protocol by the Ethics Committee for Animal Research of the Universidade Estadual de Londrina (UEL) under the protocol CEUA-UEL 26292.2012.91, and were carried out in accordance with the current guidelines for the care of laboratory animals and the ethical guidelines for investigations of experimental pain in conscious animals [27] and International Association for the Study of Pain (IASP). Experiments were conducted using male Swiss mice (20-25 g ) obtained from the Universidade Estadual de Londrina's animal facility that were housed at 22 ± 2 ºC under a 12-h light/12-h dark cycle (lights on at 06:00 a.m.) with access to food and water ad libitum. The mice were acclimatized to the laboratory for at least 1 h before testing and were used only once throughout the experiments.
Chronic constriction injury (CCI) of the sciatic nerve
Mice were anaesthetized and maintained with volatile anesthetic isoflurane (3% in O 2 ). Surgical procedures were performed as previously described [28] with modifications [14] . Briefly, the distal portion of the sciatic nerve was tied with surgical thread (catgut 4-0). In sham-operated mice, the sciatic nerve was exposed without ligation. The wound was closed and covered with iodine solution.
Electronic pressure meter test of mechanical hyperalgesia
Mechanical hyperalgesia was tested in mice as previously reported [29] . Briefly, the test consists 
Hot plate test
Mice were placed in the hot plate apparatus (EFF 361; Insight, Ribeirao Preto, SP, Brazil) maintained at 52 °C [30] . The first ipsilateral hind paw flexion reflex (nociceptive behavior) was registered. The response latency was recorded in the day before the surgery and on 7 and 7-14 days post-surgery for the experiments evaluating thermal hyperalgesia and effect of AS in acute and chronic protocols, respectively. The maximum latency (cut-off) was set at 20 s to avoid tissue damage [31] .
RT-PCR and quantitative PCR
Spinal tissue samples were homogenized in TRIzol® reagent (Life Technologies), and total mRNA were isolated according to manufacturer's directions. RNA purity was confirmed by the 260/280 ratio [32] . RT-PCR and quantitative PCR were performed using GoTaq® 2-Step RTqPCR System (Promega) on a StepOnePlus™ Real-Time PCR System (Applied Biosystems®).
The primer sequences shown in Table 1 were used, and their values were calculated as fold change relative to control after normalization to the GAPDH (glyceraldehyde 3-phosphate dehydrogenase) gene [33] [34] [35] [36] [37] .
Hepatotoxicity and nephrotoxicity
Plasma levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), urea and creatinine were used as indicators of hepatotoxicity [38] and nephrotoxicity [39] , respectively.
These assays were performed using a diagnostic kit from Labtest (Lagoa Santa, Minas Gerais, Brazil) in samples collected in the 14 th day after surgery after behavioral evaluation.
Drugs
Drugs were obtained from the following sources: Glibenclamide (GLB) and KT5823 were obtained from Sigma Aldrich (St Louis, MO, USA). 1H- [1, 2, 4] oxadiazolo [4,3, -a]quinoxalin-1-one (ODQ) was purchased from Calbiochem (San Diego, CA, USA). AS was synthesized and used as previously described [40] . The stability of stock solutions prepared in 10 mM NaOH and stored at 20°C was determined from the extinction coefficient at 250 nm (ε of 8000 M -1 cm -1 for AS) [41] . AS was prepared at 7 mg/ml of 10 mM NaOH; ODQ were diluted in
dimethylsulfoxide (DMSO) 2% in saline, KT5823 in DMSO 2% or GLB in Tween 80 5%. AS, ODQ, KT5823 or GLB solutions were re-diluted in sterile saline for in vivo administration.
Protocols
Mice were treated with AS (s.c.; dose range: 0.3-3 mg/kg; diluted in 10 mM NaOH plus saline)
at the 7 th day after CCI surgery, followed by evaluation of mechanical and thermal hyperalgesia 
Statistical analysis
The results are representative of two independent experiments and are presented as the mean ± SEM (n = 6 per group per experiment). Data were analysed using the software GraphPad Prism 6.01. Two-way repeated measure analysis of variance (ANOVA) followed by Tukey's post hoc was used to compare all groups and doses at all times when responses were measured at different time points after the stimulus injection. When an analysis was performed at a single time point, one-way ANOVA followed by Tukey's post hoc was used. Statistical differences were considered significant when P < 0.05.
Results
Single AS treatment reduces CCI-induced mechanical hyperalgesia, but not thermal hyperalgesia.
In the 7 th day after CCI surgery mice were treated with AS (s.c. bolus injection; 0.3, 1 and 3 mg/kg). AS reduced CCI-induced mechanical hyperalgesia ( Fig. 1A ) with significant effect at 5 h with 1 mg/kg of AS and between 1-7 h after the treatment with 3 mg/kg of AS. The antinociceptive effect of AS was maximal at 5 h after treatment with 3 mg/kg of AS, which was chosen for subsequent experiments. AS did not alter CCI-induced thermal hyperalgesia (Fig. 1B) after the acute single treatment.
Single AS treatment reduces CCI-induced mechanical hyperalgesia by activating the cGMP/PKG/ATP-sensitive potassium channel pathway.
In the 7 th day after CCI surgery, mice were treated with ODQ, KT5823 or GLB, followed by acute single treatment with AS (3 mg/kg, s.c.) or vehicle (diluted in 10 mM NaOH plus saline).
Mechanical hyperalgesia evaluation was performed 1, 3, 5, 7 h after AS treatment ( Fig. 2A , B, C). The ODQ treatment at 3 and 5 h ( Fig. 2A ) and KT5823 and GLB treatments at 5 h (Fig. 2B,   C ) prevented the antinociceptive effect of AS. The inhibitors ODQ, KT5823 and GLB did not alter the mechanical hyperalgesia induced by CCI per se (Fig 2A, B, C) .
AS chronic treatment reduces CCI-induced mechanical and thermal hyperalgesia
Chronic (between 7-14 days after CCI surgery) treatment with AS (3 mg/kg, s.c.) promoted a sustained reduction of CCI-induced mechanical (Fig. 3A) and thermal ( Fig. 3B) hyperalgesia.
AS reduces CCI-induced spinal cord glial cell activation.
CCI induced a significant increase of GFAP (Fig. 4A ) and Iba-1 ( Therefore, it indicates that AS reduces CCI-induced activation of astrocytes and microglia in the spinal cord, and that its effects were more pronounced upon chronic treatment compared to single acute treatment (Fig. 4A, B) .
AS reduces CCI-induced spinal cord up-regulation of pro-IL-1β, TNF-α, IL-33 and ST2
receptor mRNA expression.
CCI induced significant increase of pro-IL-1β, TNF-α, IL-33 and IL-33 receptor (ST2) mRNA expression at 7 (acute single treatment) and 14 (chronic treatment) days after surgery compared to sham group (Fig. 5) . Single AS treatment reduced pro-IL-1β (Fig. 5A ) and ST2 (Fig. 5D) mRNA expression without affecting TNF-α (Fig. 5B ) and IL-33 ( (Fig. 5) . Therefore, CCI-induced pro-hyperalgesic cytokine mRNA expression in the spinal cord was reduced by AS treatment.
Chronic AS treatment does not affect aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea and creatinine plasma levels.
Plasma levels of AST, ALT, urea and creatinine were not altered by chronic treatment (between 7-14 days after CCI surgery) with AS (3 mg/kg, s.c.) (Fig. 6 ). Therefore, AS seems to be a safe compound regarding liver and renal damage.
Discussion
Chronic pain conditions such as neuropathic pain are major health problems worldwide due to their endurance, poor availability of efficacious therapies and undesired treatment side effects.
Therefore, developing novel therapeutic strategies is necessary. Peripheral nerve injury such as CCI leads to mechanical and thermal hyperalgesia [42] [43] [44] [45] and also provokes a reaction in peripheral immune and spinal cord glial cells [46] . The current study showed that AS reduced CCI-induced neuropathic pain. Acute AS treatment inhibited mechanical hyperalgesia, and Acute and chronic AS treatments diminished the mechanical hyperalgesia while only chronic treatment was capable of reducing CCI-induced thermal hyperalgesia. Furthermore, inhibitors of the cGMP/PKG/ATP-sensitive potassium channel pathway reversed the acute analgesic effect of AS in the CCI model. Nitroxyl is capable of activating sGC to produce cGMP in other systems [22] [23] [24] . In agreement with the AS-induced activation of sGC, AS reduces acute inflammatory pain by activating the cGMP/PKG/ATP-sensitive potassium channels signaling pathway [25, 26] . Notwithstanding, there are conflicting literature data showing that the activation of cGMP mediates hyperalgesia in neuropathic pain models [47, 48] .
Activation of spinal cord microglia dominates the early glial response in the central nervous system (CNS) to peripheral nerve injury as observed by the activation and proliferation of astrocytes [4, 49] . Reactive astrogliosis has been shown to correlate with the severity of peripheral nerve injury and increased GFAP expression, which is used as a marker of altered morphology and activity [44, 46, 49, 50] . Microgliosis correlates with increased expression of CD11b and allograft inflammatory factor 1 (AIF1; also known as Iba-1) [46, 51] . AS chronic (7- 
